The 2010-2015 Prevalence of Eosinophilic Esophagitis in the USA: A Population-Based Study
Overview
Authors
Affiliations
Background And Aims: Eosinophilic esophagitis (EoE) is a chronic inflammatory disorder with increasing prevalence. However, epidemiologic data have mostly been acquired from small studies. We sought to describe the epidemiology of EoE in the USA, utilizing a large database.
Methods: We queried a commercial database (Explorys Inc, Cleveland, OH, USA), an aggregate of electronic health record data from 26 major integrated US healthcare systems from 1999 to July 2015. We identified an aggregated patient cohort of eligible patients with EoE and a history of proton-pump inhibitor use between July 2010 and July 2015, based on Systematized Nomenclature of Medicine-Clinical Terms. We calculated the prevalence of EoE among different patient groups.
Results: Of the 30,301,440 individuals in the database, we identified 7840 patients with EoE with an overall prevalence of 25.9/100,000 persons. Prevalence was higher in males than females [odds ratio (OR) 2.00; 95 % CI 1.92-2.10, p < 0.0001], Caucasians versus African-Americans and Asians (OR 2.00; 95 % CI 1.86-2.14, p < 0.0001), and adults (18-65 years) versus elderly (>65 years) and children (<18 years) (OR 1.63; 95 % CI 1.54-1.71, p < 0.0001). Compared with controls (individuals in database without EoE), individuals with EoE were more likely to have other gastrointestinal diagnoses such as dysphagia and at least one allergic condition.
Conclusions: In this large study, we found that the estimated prevalence of EoE in the USA is 25.9/100,000, which is at the lower end of prevalence rates reported in the USA and other industrial countries. We confirmed that EoE has a strong association with allergic and gastrointestinal diagnoses.
Incidence and Characteristics of Pediatric Eosinophilic Esophagitis: A Midwestern State Analysis.
Zamora-Sifuentes J, Rorie A, Kunnath S, Pauley R, Huang Pacheco A, Hopp R Children (Basel). 2025; 12(2).
PMID: 40003350 PMC: 11853838. DOI: 10.3390/children12020248.
Epidemiology of Eosinophilic Esophagitis: Really a Novel and Evolving Disease?.
Mona R, Hruz P Inflamm Intest Dis. 2025; 10(1):34-40.
PMID: 39834520 PMC: 11745509. DOI: 10.1159/000543022.
Prevalence and Costs of Eosinophilic Esophagitis in the United States.
Thel H, Anderson C, Xue A, Jensen E, Dellon E Clin Gastroenterol Hepatol. 2024; 23(2):272-280.e8.
PMID: 39486752 PMC: 11761390. DOI: 10.1016/j.cgh.2024.09.031.
The role of dupilumab in the treatment of eosinophilic esophagitis.
Syverson E, Rubinstein E, Lee J, McDonald D, Hait E Immunotherapy. 2024; 16(13):845-852.
PMID: 39073081 PMC: 11457672. DOI: 10.1080/1750743X.2024.2377060.
Ramanan S, Singh B, Gandhamaneni S, Sange I Cureus. 2024; 16(4):e58343.
PMID: 38756322 PMC: 11097238. DOI: 10.7759/cureus.58343.